Zealand Pharma

Report Publication Announcement • Dec 12, 2012

Copenhagen, 2012-12-12 10:40 CET (GLOBE NEWSWIRE) -- Zealand Pharma (NASDAQ OMX
Copenhagen: ZEAL) announces the following dates for the company’s planned
financial reporting in 2013:

14 March Annual Report 2012
15 May Interim report, 3 months 2013
29 August Interim report, 1H 2013
15 November Interim report, 9 months 2013

The Annual General Meeting will be held on Tuesday 30 April 2013, at the
company’s address; Smedeland 36, 2600 Glostrup – Copenhagen, Denmark.

The Financial Calendar for 2013 is also available in the Investor section of
the company’s website; www.zealandpharma.com.

                 # # #

For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication
Tel: +45 5060 3689, email: hlh@zealandpharma.com

About Zealand Pharma
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company
based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery,
optimization and development of novel peptide drugs and has a broad and mature
pipeline of drug candidates identified through its own drug discovery
activities. The company’s focus lies in the field of diabetes/metabolic
diseases, and its lead drug invention is lixisenatide (Lyxumia® 1), a
once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type
2 diabetes. In November 2012, lixisenatide was given a CHMP positive opinion in
Europe and a regulatory filing in the United States is expected in December
2012.

Zealand Pharma has a partnering strategy for the development and
commercialization of its products and in addition to the collaboration with
Sanofi in Type 2 diabetes, the company has partnerships with Boehringer
Ingelheim in diabetes/obesity, Abbott in acute kidney injury and Helsinn
Healthcare in chemotherapy induced diarrhea. Zealand Pharma focuses its
activities in disease areas where existing treatments fail to adequately serve
patient needs and where the market potential for improved treatments through
the use of peptide drugs is high. For further information:
www.zealandpharma.com

1. Lyxumia is the proprietary name submitted to the EMA for lixisenatide. The
   proprietary name for lixisenatide in the United States is under consideration.
   Lixisenatide is not currently approved or licensed anywhere in the world.